Structure via PubChem · Public domain (PubChem)
selexipag
Sign in to saveAlso known as ACT-293987, NS-304, Uptravi®, NS 304, ACT 293987
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. It is taken by mouth or administered intravenously.
In the Vinony graph
Vinony's link graph records 286 inbound references to selexipag, and connects out to biological half-life, clonixin and selenium.
Vinony files it under Acetamides, Acylsulfonamides and Carboxamides.
Vinony links it to 12 Wikipedia language editions.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 444391072
- Drug.image
- Selexipag.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Uptravi
- Drug.DailyMedID
- Selexipag
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.class
- prostacyclin receptor agonist
- Drug.ATC_prefix
- B01
- Drug.ATC_suffix
- AC27
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 49%
- Drug.protein_bound
- 99%
- Drug.metabolism
- Activation by carboxylesterases, inactivation by CYP2C8 and others
- Drug.metabolites
- ACT-333679, the free acid (active metabolite)
via Wikipedia infobox
Chemical data
- Formula
- C26H32N4O4S
- Molecular weight
- 496.6 g/mol
- IUPAC name
- 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
- SMILES
- CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
- InChIKey
- QXWZQTURMXZVHJ-UHFFFAOYSA-N
- XLogP
- 3.8
- Polar surface area
- 110 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2015
- Admin. routes
- oral, parenteral
- Indications
- Recurrent thrombophlebitis, pulmonary arterial hypertension, idiopathic and/or familial pulmonary arterial hypertension, idiopathic pulmonary arterial hypertension
via ChEMBL · EBI
Research
368 papers- Selexipag for the Treatment of Pulmonary Arterial Hypertension.The New England journal of medicine · 2015
- Selexipag.2006
- Selexipag.2012
- Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review.Clinical therapeutics · 2024
- Selexipag for pulmonary arterial hypertension.Australian prescriber · 2021
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 496.214427
- Has use
- medication
Show 8 more facts
- chemical formula
- C₂₆H₃₂N₄O₄S
- defined daily dose
- 1.8
- canonical SMILES
- CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
- World Health Organisation international non-proprietary name
- selexipag
- medical condition treated
- pulmonary hypertension
- subject has role
- antihypertensive drug
- physically interacts with
- Prostaglandin I2 receptor
- Commons category
- Selexipag
via Wikidata · CC0
~6 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- Society and culture
- Economics
- References
- External links
{{Infobox drug | Verifiedfields = changed | verifiedrevid = 444391072 | image = Selexipag.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Uptravi | Drugs.com = | MedlinePlus = | DailyMedID = Selexipag | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth, intravenous | class = prostacyclin receptor agonist | ATC_prefix = B01 | ATC_suffix = AC27 | ATC_supplemental =
Excerpted from Wikipedia’s “selexipag” article, available under the CC BY-SA 4.0 licence.
Gallery (3)
Available in 12 languages
via Wikidata sitelinks · CC0